Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.44 |
| ▸ | ATR | Q13535 | 5/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 10/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3461753 | 0.92 | NTRK1 (0.46) | PIK3CDPIK3CAPIK3CGTYRO3ATR | |
| SCHEMBL3460695 | 0.91 | NTRK1 (0.46) | PIK3CDPIK3CAPIK3CGTYRO3ATR | |
| SCHEMBL3462076 | 0.91 | TYRO3 (0.47) | TYRO3ATRNTRK1NTRK3NTRK2 | |
| SCHEMBL3460094 | 0.89 | ATR (0.50) | TYRO3ATRNTRK1NTRK3NTRK2 | |
| SCHEMBL3461400 | 0.88 | NTRK1 (0.47) | TYRO3ATRNTRK1NTRK3NTRK2 | |
| SCHEMBL3460556 | 0.87 | NTRK1 (0.51) | TYRO3ATRNTRK1NTRK3NTRK2 | |
| SCHEMBL3460807 | 0.87 | TYRO3 (0.48) | TYRO3ATRNTRK1NTRK3NTRK2 | |
| SCHEMBL3460806 | 0.86 | NTRK1 (0.52) | TYRO3ATRNTRK1NTRK3NTRK2 | |
| SCHEMBL14238402 | 0.86 | TYRO3 (0.47) | TYRO3ATRNTRK1NTRK3NTRK2 | |
| SCHEMBL3459730 | 0.86 | TYRO3 (0.47) | TYRO3ATRNTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | PIK3CD 375/4885PIK3CA 463/4885PIK3CG 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.